J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...
"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...
LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...
We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.
GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...
GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.
British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation ...